...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Infectious Disorders - Drug Targets >Drug Targets in Herpes Simplex and Epstein Barr Virus Infections
【24h】

Drug Targets in Herpes Simplex and Epstein Barr Virus Infections

机译：单纯疱疹和爱泼斯坦巴尔病毒感染的药物靶标

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Herpes simplex virus (HSV) and Epstein Barr Virus (EBV) are Herpesviridae. Although infections are often subclinical, HSV can cause mild to severe diseases, especially in immunocompromised patients. EBV infections are also often asymptomatic but this virus may be associated to carcinoma in immunocompetent patients and to severe diseases in immunocompromised patients.nnThese viruses establish latency, in neuronal cells for HSV and in B-cells for EBV, and may reactivate, with or without symptoms.nnThere are few drugs licensed for the treatment of HSV infections. Most of them target the viral DNA polymerase, in which acyclovir remains the reference treatment some thirty years after its discovery. The emergence of resistant viral strains, mainly in immunocompromised patients, highlights the crucial need for the development of new anti-herpes drugs that can inhibit infection by both wild-type viruses and acyclovir-resistant strains.nnNo antiviral drug has been yet licensed for EBV. Therapies mainly rely on control of immunosuppression and/or immunotherapies. Antiviral drug such as acyclovir and ganciclovir have been used with limited impact except when used with drugs that induce EBV lytic cycle.nnOver the last few years, significant efforts have been made to set up a range of strategies for the identification of potential new antiviral drugs. For HSV, and more strikingly for EBV, there is a crucial need for antiviral drug active on latent virus. One alternative is to develop drugs with different mechanisms of action. The present article reviews potential targets, viral and cellular, for which specific inhibitors have been identified.
机译：单纯疱疹病毒（HSV）和爱泼斯坦巴尔病毒（EBV）是疱疹病毒科。尽管感染通常是亚临床的，但HSV可以引起轻度至重度疾病，尤其是在免疫功能低下的患者中。 EBV感染也通常是无症状的，但该病毒可能与免疫功能正常的患者的癌症以及免疫功能低下的患者的严重疾病有关。这些病毒在HSV的神经元细胞和EBV的B细胞中建立潜伏期，有或无很少有被许可用于治疗HSV感染的药物。它们中的大多数靶向病毒DNA聚合酶，在阿昔洛韦被发现大约30年后，阿昔洛韦仍然是参考疗法。主要在免疫功能低下的患者中出现抗药性病毒株，这突出表明了对开发新的抗疱疹药物的迫切需求，该药既可以抑制野生型病毒也可以对无环鸟苷耐药菌株感染。 。治疗主要依赖于免疫抑制和/或免疫治疗的控制。除与阿昔洛韦和更昔洛韦这样的抗病毒药物一起使用外，除非与诱导EBV裂解周期的药物一起使用，否则影响有限。nn在过去的几年中，为确定潜在的新型抗病毒药物做出了一系列努力。对于HSV，尤其对于EBV，迫切需要对潜伏病毒有活性的抗病毒药物。一种选择是开发具有不同作用机理的药物。本文概述了潜在的靶标，包括病毒和细胞，已经确定了特异性抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号